Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 1, 2004, Pages 61-68

  Génissel, Patrick ^a,c   Chodjania, Y ^b   Demolis, J L ^b   Ragueneau, I ^b   Jaillon, P ^b  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Animal; Human; Modified release; Pharmacokinetics; Trimetazidine

Indexed keywords

TRIMETAZIDINE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG MECHANISM; HUMAN; MALE; MULTIPLE DRUG DOSE; NONHUMAN; NORMAL HUMAN; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; STEADY STATE; SUSTAINED RELEASE PREPARATION; SWINE; TABLET;

EID: 2442547533     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190575     Document Type: Article

References (7)

1. Detry J.M., Sellier P., Pennaforte S., Cokkinos D., Dargie H., Mathes P. (1994): Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br. J. Clin. Pharmacol., 37, 279-288.
2. Szwed H., Sadowski Z., Elikowski W., Koronkiewicz A., Mamcarz A., Orszulak W., Skibinska E., Szymczak K., Swiatek J., Winter M. (2001): Combination treatment instable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur. Heart. J., 22, 2267-2274.
3. Manchanda S.C., Krishnaswami S. (1997): Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart, 78, 353-357.
4. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. (2000): The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res., 86, 580-588.
5. CPMP/EWP/280/96 (1999): Note for guidance on modified release oral and transdermal dosage forms: Section II (Pharmacokinetic and clinical evaluation). Adopted by EMEA (European Agency for Evaluation of Medicinal Products). London.
6. Mulcahy D. (1999): "Circadian" variation in cardiovascular events and implications for therapy. J. Cardiovasc. Pharmacol., S34, 3-8.
7. Sellier P., Broustet J.P. (2003): Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am. J. Cardiovasc. Drugs, 3, 361-369.